Skip to content
Peptigraph home

5-Amino-1MQ vs MOTS-c: What the Research Shows

5-Amino-1MQ and MOTS-c side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
NNMT inhibitor (not a peptide)Not FDA approved · research chemical5-Amino-1MQNNMT inhibitor (not a peptide) with no human studies; in diet-induced obese mice, 5-amino-1MQ plus a low-fat diet promoted whole-body adiposity and weight loss.[3]GLP-1 & metabolicMitochondrial-derived peptidePCAC voted 7–5 for 503A (Jul 2026)MOTS-cMitochondrial-derived peptide; human studies found only measured the body's own circulating levels (for example after repeated heat treatment), not administered MOTS-c.[8]GLP-1 & metabolic
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider 5-Amino-1MQ if…

  • you are tested in sport and want to avoid a WADA-prohibited substance: MOTS-c is prohibited by WADA at all times (check 5-amino-1MQ's own status separately)[2]

Consider MOTS-c if…

  • you are weighing human evidence that, in our search, only measured the body's own MOTS-c (none gave it as a treatment): exercise raised plasma MOTS-c in non-Hispanic White survivors but not Hispanic survivors[10]

What they have in common

  • Only animal or lab studies of 5-amino-1MQ were found (e.g. obese mice): combined with a low-fat diet it promoted marked loss of adiposity and weight[3]
Neither is FDA approved for any use in people. MOTS-c is prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 10 of 12 fields where the two differ. Category, Half-life are the same or both unknown.

Field5-Amino-1MQMOTS-c
ClassNNMT inhibitor (not a peptide)Mitochondrial-derived peptide
Also called5-amino, 1MQmots
FDA statusNot FDA approved · research chemicalPCAC voted 7–5 for 503A (Jul 2026)
PCAC vote, Jul 2026Not on the Jul 2026 agendaPCAC voted 7–5 for the 503A list (Jul 2026); not finalized
WADAWADA status unclear5-Amino-1MQ is not named. S4.4 covers AMPK activators, PPAR-delta agonists and Rev-erb agonists by example, and nothing there names an NNMT inhibitor. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times.
Anti-doping detectionNone reportedanti-doping literature, as of 2 Oct 2026
  • A plasma (blood) test for MOTS-c has been validated to WADA standards.PMID 30394592
Evidence strengthAnimal evidence, 2 of 4Strongest: Scientific reports 2022, PMID 35013352Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654
Human studies we summarised0 human (0 randomized or controlled) of 4 summarised7 human (4 randomized or controlled) of 15 summarised
Typical study doses
Vial sizes sold5 mg, 10 mg5 mg, 10 mg, 20 mg, 40 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

5-Amino-1MQ and MOTS-c together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Open the stack page

A small-molecule enzyme blocker versus a 16-amino-acid mitochondrial peptide

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial 12S rRNA that, per its discovery paper, regulates insulin sensitivity and metabolic homeostasis.[20]

5-amino-1MQ (5MQ) is a small-molecule inhibitor of the enzyme NNMT. One paper tested it at 0.1 to 500 micromolar on a HeLa cervical cancer cell line, a cell-culture result with no body-weight endpoint.[4]

In the original mouse report, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity. This is mouse prevention data.[20]

What the human papers do and do not show

In a 16-week exercise trial in breast-cancer survivors, circulating MOTS-c rose among non-Hispanic White participants. The peptide itself was not administered.[10]

Serum MOTS-c did not differ between adults with obesity and adults with normal body mass index in an 85-person study (14.33 vs 13.67 pg/mL).[21]

In diet-induced obese mice, 5-amino-1MQ combined with a low-fat diet produced marked fat and weight loss, which switching to the low-fat diet alone did not.[3]

Common questions

5-amino-1MQ vs MOTS-c: what is the difference?

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. 5-amino-1MQ is covered above as a small-molecule NNMT inhibitor.[20]

Has MOTS-c been given to humans?

The human papers cited here measured the body's own MOTS-c, for example after exercise, rather than administering it.[10]

Which one has more research behind it?

The cited MOTS-c mouse papers span obesity, insulin resistance and muscle loss; in one, treatment attenuated muscle loss to a 5% reduction against about 15% with immobilization. The cited 5-amino-1MQ work is one obese-mouse paper plus cell experiments.[22]

Sources

  1. 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
  4. 4Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021PMID 33645410Accessed 2 Oct 2026
  5. 5PubMed search: "5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab] (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: nicotinamide N-methyltransferase[tiab] AND (quinolinium[tiab] OR 5-amino-1MQ[tiab] OR "5-amino-1-methylquinolinium"[tiab] OR 5MQ[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
  8. 8Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
  9. 9Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
  10. 10Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
  11. 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("MOTS-c"[tiab] OR MOTSc[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
  18. 18PubMed search: ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (0 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  19. 19PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  20. 20The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.Cell metabolism · 2015PMID 25738459Accessed 2 Oct 2026
  21. 21MOTS-C levels ın ındividuals with and without obesity and ıts association with ınflammation, insulin resistance and endothelial dysfunction.Archives of endocrinology and metabolism · 2025PMID 41004666Accessed 2 Oct 2026
  22. 22Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration.American journal of physiology. Endocrinology and metabolism · 2024PMID 38170165Accessed 2 Oct 2026

Found an error? Report a correction.